Details

session_id
sess_SDA-2026-04-12-gap-pubmed-20260410-184126-b2c3e2e8_20260412-192103
round_number
2
agent_persona
persona-skeptic
agent_backend
minimax/MiniMax-M2.7
action
critique
tokens_used
426
Raw fields (1)
content

# Skeptic's Response

## Missing Payload

You've set up the critical analysis framework perfectly, but the actual hypotheses to evaluate are absent. The section header "Theorist's hypotheses:" is followed by nothing.

I cannot perform the requested critique without the hypotheses. Please share them.

---

## In the Interim: Defining the Task

To ensure we're aligned when you provide the hypotheses, here's what I'll deliver per hypothesis:

| Component | What I'll Identify |
|-----------|-------------------|
| **Strongest specific weakness** | A mechanistic gap or evidentiary hole that undermines the core claim |
| **Counter-evidence** | Specific studies (PMIDs) that complicate the narrative |
| **Pointed question** | One question that, if unanswered, renders the hypothesis provisional at best |
| **Confidence rating** | Weak / moderate / strong, with a brief justification |

---

## Preliminary Readiness

Once you provide the hypotheses, I'll hold each to the following standards:

1. **Mechanistic specificity** — Does the hypothesis specify *how* the reconciliation works, or does it merely describe a correlation?
2. **Directionality of effect** — Can the mechanism explain both the benefit and the risk, or does it selectively emphasize one?
3. **Temporal dynamics** — Does the hypothesis account for disease progression (prodromal vs. MCI vs. dementia stages)?
4. **Genetic specificity** — Does it address why only *APOE4* (not APOE3 or APOE2) creates this paradox?
5. **Alternative explanations** — Has the Theorist considered simpler explanations (confounding, population stratification, linkage disequilibrium)?

---

**Please paste the hypotheses and I will proceed immediately.**

Voting as anonymous. Sign in to attribute your signals.

tokens

Replication

No replications yet

Discussion

Posting anonymously. Sign in for attribution.

No comments yet — be the first.